Literature DB >> 2837137

Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus.

J P Flandrois1, G Fardel, G Carret.   

Abstract

The early stages of the time-killing curves of vancomycin and LY146032 have been studied, by use of short sampling intervals, for three strains of Staphylococcus aureus. Both vancomycin and LY146032 killed S. aureus, but the time-killing curves differed: the effect of vancomycin was slow, limited, and not related to the concentration of the drug, whereas that of LY146032 was rapid, extensive, and related to concentration. When strains ATCC 25923 and CIP 6525 were exposed to LY146032, the population decreased exponentially with time. The killing rate was constant and linked to the concentration by a Michaelis-Menten relationship. The maximum killing rate and the affinity constant of LY146032, estimated from the data transformed by the Lineweaver-Burk method, differed for the two strains. The concentration of the antibiotic at which killing theoretically begins (estimated by linear regression using the logarithm of the concentration) is of the same magnitude as the MIC of LY146032, which indicates the pure bactericidal mode of action of the drug. S. aureus ATCC 12600 was more resistant to the bactericidal effect of the two drugs, and its killing curve did not conform to the model described here.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2837137      PMCID: PMC172200          DOI: 10.1128/AAC.32.4.454

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.

Authors:  P Huovinen; P Kotilainen
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

2.  In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

3.  Correlation between "methicillin resistance" and serotype in Staphylococcus.

Authors:  Y A Chabbert; J Pillet
Journal:  Nature       Date:  1967-03-18       Impact factor: 49.962

4.  In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; C Thauvin; B Gerson; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

5.  In vitro activity of LY146032 (daptomycin), a new peptolide.

Authors:  F Ehlert; H C Neu
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

6.  Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.

Authors:  K Machka; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

7.  In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.

Authors:  J H Jorgensen; L A Maher; J S Redding
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

8.  In vitro activity of combinations of antibiotics against Staphylococcus aureus resistant to gentamicin and methicillin.

Authors:  S Dixson; W Brumfitt; J M Hamilton-Miller
Journal:  Infection       Date:  1985 Jan-Feb       Impact factor: 3.553

9.  In vitro activity of teichomycin against isolates of gram-positive bacteria.

Authors:  A Fietta; C Bersani; P Mangiarotti; G Gialdroni Grassi
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

  9 in total
  16 in total

1.  Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model.

Authors:  K Vance-Bryan; T A Larson; J C Rotschafer; J P Toscano
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

3.  Mathematical model for comparison of time-killing curves.

Authors:  F Guerillot; G Carret; J P Flandrois
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

4.  Bactericidal activity of vancomycin in cerebrospinal fluid.

Authors:  M Nagl; C Neher; J Hager; B Pfausler; E Schmutzhard; F Allerberger
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Staphylococcus aureus ventriculitis treated with single-dose intraventricular vancomycin or daptomycin (LY146032): bacterial and antibiotic kinetics in hydrocephalic rabbits.

Authors:  C S Haworth; M W Sobieski; W M Scheld; T S Park
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

6.  Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

7.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Authors:  K C Lamp; M J Rybak; E M Bailey; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.

Authors:  M J Rybak; E M Bailey; K C Lamp; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 9.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

10.  In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  E Löwdin; I Odenholt; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.